Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Recruiting

Phase Results N/A

Eligibility Criteria

Inclusion criteria:
Cohort A (patients switched from VKA to Pradaxa)
- Written informed consent prior to participation.
- Female or male patients ≥ 20 years of age with a diagnosis of non-valvular atrial fibrillation (NVAF).
- At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.
- Patients switched to Pradaxa prior to baseline assessment according to the physician's discretion and the Summary of Product Characteristics (SmPCs)/reimbursement criteria.
OR Cohort B (patients newly initiated Pradaxa or VKA)
- Written informed consent prior to participation.
- Female or male patients ≥ 20 years of age, newly diagnosed with NVAF, and no previous treatment for stroke prevention (no use of any OAC within 1 year prior to enrolment).
- Patients initiated stroke prevention treatment with Pradaxa or VKA according to the physician's discretion and the SmPCs/reimbursement criteria.
Exclusion criteria:
- Contraindication to the use of Pradaxa® or VKA as described in the SmPCs.
- Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in NVAF.
- Current participation in any clinical trial of a drug or device.
- Current participation in an AF-related registry, e.g. the Gloria AF program.